Dr. Flint R. Packer, D.O.
Family Medicine (Family Medicine Physician)
3614 Washington Pkwy
Idaho Falls, ID 83404
Who else practices at this address →
Bonneville County includes primary care (1% of residents) shortage areas. About shortage areas
- Medicare participating
At a glance
- Medical school
- Des Moines University of Osteopathic Medicine and Health Sciences (1997)
- Years since graduation
- 29
- In the NPI registry since
- 2007
- Medicare patients seen, 2024
- 386
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is
Education and training
- 1997Medical school: Des Moines University of Osteopathic Medicine and Health Sciences
- 2007Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier
Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Family Medicine Physician primary
ID license O233
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Hospitals
- Mountain View Hospital Idaho Falls, ID
- Eastern Idaho Regional Medical Center Idaho Falls, ID
- Idaho Falls Community Hospital, LLC Idaho Falls, ID
Medical groups
- Family First Medical Center PLLC (17 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 386
- Services billed
- 3,197
- Patients’ average age
- 74
| Service | Times | Patients |
|---|---|---|
| Chronic care management services, first 20 minutes of clinical staff time directed by health care professional, per calendar month | 636 | 213 |
| Insertion of needle into vein for collection of blood sample | 375 | 226 |
| Established patient office or other outpatient visit, 30-39 minutes | 240 | 156 |
| Chronic care management services for two or more chronic conditions, additional 20 minutes of clinical staff time directed by health care professional, per calendar month | 193 | 97 |
| Annual wellness visit, includes a personalized prevention plan of service (pps), subsequent visit | 183 | 183 |
| Established patient office or other outpatient visit, 20-29 minutes | 181 | 126 |
| Annual depression screening, 5 to 15 minutes | 181 | 181 |
| Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count | 110 | 103 |
| Influenza vaccine, quadrivalent, preservative free, 0.5 ml dosage | 103 | 102 |
| Administration of influenza virus vaccine | 100 | 99 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 29 companies reported 82 payments worth $1,354 in total to this clinician.
| AbbVie Inc. | $348 |
|---|---|
| Lilly USA, LLC | $99.87 |
| Antares Pharma, Inc. | $86.28 |
| Astellas Pharma US Inc | $85.49 |
| Phathom Pharmaceuticals, Inc. | $64.97 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | $50.11 |
| Dexcom, Inc. | $49.66 |
| Ionis Pharmaceuticals, Inc. | $48.99 |
| Food and Beverage | $1,354 |
|---|
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 3 industry-funded studies in 2025, from 1 companies. The companies reported $132,804 in research payments for these studies, mostly to the institutions running them.
- A Study of Orforglipron (LY3502970) Compared With Semaglutide in Participants With Type 2 Diabetes Inadequately Controlled With Metformin
Eli Lilly and Company · Completed · NCT06045221 - A Study of Orforglipron (LY3502970) in Adult Participants With Type 2 Diabetes and Inadequate Glycemic Control With Diet and Exercise Alone
Eli Lilly and Company · Completed · NCT05971940 - A Study of Bimagrumab (LY3985863) and Tirzepatide (LY3298176), Alone or in Combination, in Participants With Obesity or Overweight With Type 2 Diabetes
Eli Lilly and Company · Withdrawn · NCT06901349
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.